Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

Interleukins-6 (IL-6)/GP130 signaling pathway represents a promising target for cancer therapy due to its critical role in survival and progression of multiple types of cancer. We have identified Bazedoxifene, a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Hui, Bid, Hemant Kumar, Chen, Xiang, Wu, Xiaojuan, Wei, Jia, Bian, Yang, Zhao, Chengguang, Li, Huameng, Li, Chenglong, Lin, Jiayuh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495564/
https://www.ncbi.nlm.nih.gov/pubmed/28672024
http://dx.doi.org/10.1371/journal.pone.0180297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495564/
https://www.ncbi.nlm.nih.gov/pubmed/28672024
http://dx.doi.org/10.1371/journal.pone.0180297

Ejemplares similares